← Back to Search

Hormone Therapy

Male Contraceptive Gel for Birth Control

Phase 2
Waitlist Available
Research Sponsored by Health Decisions
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male participants must be sexually active with a stable, mutually monogamous female partner for at least 1 year prior to screening and have normal reproductive state as demonstrated by specified criteria
Good health as confirmed by medical history, physical examination, and clinical laboratory tests of blood and urine at the time of screening
Must not have
Male participants who have participated in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit
Female participants who desire to become pregnant during the study, are breastfeeding, have known or suspected current alcoholism or drug abuse, or are currently pregnant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a gel that men can use to prevent pregnancy. The study involves couples, with a focus on the male partner applying the gel. The gel works by lowering sperm count, making it less likely for the female partner to get pregnant.

Who is the study for?
This trial is for healthy men aged 18-50, with a BMI under 33, in stable relationships, and not seeking fertility within the next two years. Participants must have normal sperm counts and testosterone levels, no history of hormone treatments in the past six months, and agree to use contraception initially.
What is being tested?
The study tests a daily gel combining Nestorone® (NES) and Testosterone (T) as a form of male birth control. The goal is to develop an effective contraceptive method for men by applying this gel regularly.
What are the potential side effects?
Potential side effects are not explicitly listed but may include skin reactions at the application site or hormonal changes such as mood swings or changes in libido due to testosterone alterations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man in a stable relationship for over a year and have normal reproductive health.
Select...
My recent health checks and lab tests show I am in good health.
Select...
I am a healthy woman aged 18-34, with regular periods, a uterus, and at least one ovary.
Select...
I am a man aged 18-50, with a BMI under 33, and haven't used androgens in the last 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am a male who hasn't been in a drug trial in the last 30 days.
Select...
I am not pregnant, breastfeeding, planning to become pregnant, or have a current alcohol or drug abuse issue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nestorone (NES) + testosterone (T) combined gelExperimental Treatment1 Intervention
A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally (NES/T gel). The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nestorone + Testosterone Combination Gel
2017
Completed Phase 1
~20

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for male birth control include hormonal regulation and physical barriers. Hormonal regulation, such as the use of a topical gel combining testosterone and progestin, works by suppressing the production of sperm through the inhibition of gonadotropins, which are hormones necessary for spermatogenesis. This method is significant for male birth control patients as it provides a reversible and non-invasive option. Physical barriers, like condoms, prevent sperm from reaching the egg, offering an immediate and effective method of contraception without hormonal intervention. Both methods are crucial as they provide diverse options catering to different needs and preferences of male birth control patients.
Future directions in contraception.[Non-oral administration of progesterone: experiences and possibilities of the transvaginal route].The problem of medicating women like the men: conceptual discussion of menstrual cycle-dependent psychopharmacology.

Find a Location

Who is running the clinical trial?

Health DecisionsLead Sponsor
30 Previous Clinical Trials
13,582 Total Patients Enrolled
Population CouncilOTHER
51 Previous Clinical Trials
62,943 Total Patients Enrolled
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,068 Previous Clinical Trials
2,747,124 Total Patients Enrolled
Diana Blithe, PhDStudy DirectorEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2 Previous Clinical Trials
2,872 Total Patients Enrolled

Media Library

Nestorone + Testosterone Combination Gel (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03452111 — Phase 2
Male Birth Control Research Study Groups: Nestorone (NES) + testosterone (T) combined gel
Male Birth Control Clinical Trial 2023: Nestorone + Testosterone Combination Gel Highlights & Side Effects. Trial Name: NCT03452111 — Phase 2
Nestorone + Testosterone Combination Gel (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03452111 — Phase 2
~59 spots leftby Dec 2025